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Primary ciliary dyskinesia (PCD) is a genetic disease characterized by abnormal ciliary structure and
function and impaired mucociliary clearance. Because patients with PCD use cough clearance as an









 secretion and mucin release by




43% to 89% predicted) in a double blind, randomized, crossover study after aerosolization of a sin-
gle dose of UTP (5 mg/ml, 3.5 ml) or vehicle (0.12% saline, 3.5 ml). Clearance during cough (whole













 particles via gamma camera scanning over 120 min. Safety parameters were recorded
during and after drug delivery. Aerosolized UTP improved whole-lung clearance during cough as






























 0.02). Aerosolized UTP is safe, with no serious adverse effects. Whole-lung clear-
ance during cough in patients with defective ciliary function is enhanced after inhalation of UTP.
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Primary ciliary dyskinesia (PCD) is a genetic disease charac-
terized by abnormal ciliary ultrastructure and function, im-
paired mucociliary clearance, and chronic lung, sinus and mid-
dle ear disease (1, 2). Patients with PCD depend on cough for
airway clearance, and the cornerstone of the treatment of





-triphosphate (UTP) improves mucociliary
clearance (MCC) in normal individuals and, when used in
combination with amiloride, in patients with CF (7, 8). The ac-
tions of UTP on MCC are mediated by activation of a non-













 receptors, and by increases in intracellular
calcium, to stimulate ciliary beat frequency, (CBF) release





Triphosphate nucleotides do not stimulate the defective
cilia in PCD, but might favorably affect cough-clearable air-
way secretions via modulation of the liquid and mucin content
of airway secretions. Another way of stating this is that pa-
tients with PCD provide a genetic model for testing whether
UTP may affect nonciliary aspects (ion transport, mucins) of
the clearance of airway secretions during cough. The aim of
the present study was to evaluate the safety and biologic effi-
cacy of UTP, delivered in an aerosol to patients with PCD, in
assisting clearance during cough. UTP has been shown to be
safe and effective in normal subjects and patients with lung
disease (cystic fibrosis; CF) (7, 8). As a measure of biologic ef-
ficacy, we tested the effects of UTP on the rate of clearance
during cough of radiolabeled insoluble particles from the air-
ways, with predetermined periods of “controlled” (directed)






We studied 12 patients with PCD (four males and eight females). The




was 65.5% predicted (range: 43% to 89% predicted). All subjects had
clinical and radiologic evidence of bronchiectasis; five subjects had si-
tus inversus totalis. All subjects were in a stable clinical state upon en-
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productive of variable reported amounts of sputum. Subjects were ex-
cluded if they were considered to have significant intercurrent infec-
tion, defined as a change in cough or sputum production or increased
dyspnea within 2 wk of screening. No patients had any history sugges-
tive of significant asthma. As a part of the study protocol, all subjects
were treated with oral antibiotics (appropriate to their respiratory
flora) for 1 wk before the study. Subjects were asked to withhold in-
haled and oral bronchodilators on the morning of a study day, but
continued other medications and physical therapy as usual.
Screening included a complete history and physical examination,









), routine screening blood tests, an electrocardiogram (ECG),
and a pregnancy test in females. Samples of cilia were obtained by the
nasal scrape biopsy technique, and ciliary ultrastructural abnormali-
ties were proven by electron microscopic studies (12).
Informed consent was obtained under the auspices of the Commit-
tee on the Protection of the Rights of Human Subjects of the Univer-
sity of North Carolina at Chapel Hill.
 
Drug Preparation and Storage
 
A 10% stock solution of UTP was prepared for administration by dis-
solving dry uridine-5-triphosphate powder (98.9% UTP; Plenum Sci-
entific Research Inc., Hackensack, NJ and Inspire Pharmaceuticals,
Research Triangle Park, NC) in 0.12% saline. Aliquots of 0.22 ml of








 C until the day of the study,
when they were each thawed and diluted with 3.78 ml 0.12% saline to
achieve a 4 ml volume of the appropriate concentration (5 mg/ml) for
administration. To ensure that the investigators remained blinded, al-
iquots of stock UTP and vehicle solution (0.12% [hypotonic] saline)
were paired, labeled by an unblinded observer, and kept under the
same conditions. The final volume of both UTP and vehicle placed in
the nebulizer for aerosolization was 3.5 ml (i.e., 0.5 ml of the 4 ml was




The study was a double-blind crossover study conducted on two sepa-
rate days with at least 48 h between study days to ensure sufficient













 particles, patients either received vehicle or UTP alone
on the first study day, followed by the alternate solution on the second
study day. A scan was performed at 24 h to assess residual deposition.
Delivery was double-blinded by labeling the appropriate vial with a
randomization code drawn up by an independent observer, and by
following a preordained, computer-generated, random sequence of
delivery. Following study completion, it was verified that all patients
received the appropriate assigned study drug treatment. Figure 1 illus-
trates the study protocol in outline form, with the time points of the
various interventions.
 
Drug Delivery and Measures of Clearance
During Cough
 
Prior to inhalation of study solution on Day 1, a xenon-133 equilib-
rium scan was obtained for each subject as a reference image of the
 
whole lung, for defining regions of interest (ROIs) related to the dep-
osition and clearance of marker, and for calculating central-to-periph-
eral (C/P) deposition ratios for each study day (7, 8). On all study
days, a background scan was done for 15 min to determine back-
ground gamma counts. Following the background scan on each study
















 mass median aerodynamic diameter [MMAD], 1.25
geometric standard deviation [GSD]; Mallinckrodt, St. Louis, MO)
generated by a spinning top generator (13). Deposition on different
days was matched by controlling tidal flow (500 ml/min) and breath-
ing frequency (15/min). This was achieved by having the patient mon-









Ci was deposited in the lungs, a dose sufficient
for clearance measurements. The subjects then moved to sit in front
of the gamma camera (Apex 415, interfaced with an Elscint Model
109 computer [Elscint, Israel]) for two initial 2-min scans. Immediately
after these scans, the subjects inhaled the solution (3.5 ml) coded for








) over a 17- to 20-min period
via a finger-activated jet nebulizer (Model 646; DeVilbiss Healthcare
Inc., Somerset, PA) powered by a compressed air generator (DeVil-
biss Pulmo-Aide Model 5610D; flow rate 7 to 9 L/min). The breathing
pattern of inhalation was predefined to optimize deposition of drug
on airway surfaces: for each cycle, initial exhalation to FRC was fol-
lowed by finger activation of the nebulizer and slow inhalation of the
aerosol to TLC over a period of 3 to 4 s, with a 3- to 4-s breath hold,
and slow exhalation over a 3- to 4-s period. All subjects breathed in









 18 to 20 min. Nebulization was stopped when an aerosol
cloud was no longer visibly produced by the nebulizer. At this point, a




 0.5 ml was left in the nebulizer.
During the 2 h after inhalation of the radiolabeled marker, sub-
jects sat in front of the gamma camera and sequential 2-min images
were obtained (two 2-min images for the first 4 min of every 10-min
period) (Figure 1). During inhalation, and for 30 min afterward, blood







ration were monitored in nine of the 12 subjects. Following all study





Previous data suggested that, as predicted, there is no MCC in pa-
tients with PCD without cough (3, 4, 14). To determine baseline clear-
ance under the laboratory conditions at the University of North Caro-
lina, and the effect of UTP versus vehicle, we performed pilot studies
of four patients with PCD, measuring clearance after aerosolization of
either UTP or vehicle in the same fashion as that described earlier.
There was little or no baseline clearance in any of the subjects in the
absence of cough with either vehicle or UTP. These data, coupled
with those from the literature, support the notion that nucleotides
(UTP) do not stimulate CBF/MCC in PCD in the absence of cough,
and that cough may be used as an outcome measure to assess clear-
ance during cough following an intervention such as aerosolized deliv-
ery of drug in comparison with vehicle (3, 14). The pilot data also sug-
gested that some patients might not be able to completely suppress
cough during and immediately after aerosol inhalation. We therefore








 0 to 20 min represents the period of delivery of solu-
tion). Some patients coughed spontaneously during and after inhala-
tion of study drug; these coughs were counted; the total number of
coughs (spontaneous plus controlled) was limited to 90 during the 60-
min time period (e.g., if a subject coughed spontaneously 15 times, 75
controlled coughs were performed). Controlled coughs were per-
formed by having each subject cough under the direction of the inves-
tigators into a spirometer. Flow was displayed on an oscilloscope, so
that the subject could follow the same expiratory flow pattern as
closely as possible during each cough. The peak flow rate (PFR; L/s)
of each controlled cough was recorded on a Macintosh computer (Ap-
ple Computer, Cupertino, CA) using a data acquisition system (Mac-
lab; Apple). When available for collection, sputum was obtained dur-
ing these cough maneuvers as soon as possible after aerosol delivery
was completed, and the time taken to produce the sample was re-
corded (minutes). The sputum was collected in a manner designed to
Figure 1. Schematic outline of cough-clearance protocol for each
study day, denoting time points and interventions. Time 5 0 rep-
resents the start of study-solution inhalation. The total number of
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minimize salivary contamination, using the dental cotton technique.
In addition, the time elapsed between the start of the study and spu-
tum production was measured. The sputum was double wrapped in








 C pending studies of sputum weights, ion
content, and rheologic tests. The last of these were performed with













 content (16, 17). Included in these mea-
sures were Avg Log G (an index of the mechanical impedance of spu-
tum); the MCC index and cough-clearance index were calculated.
These are unitless measures predicted from model cough and MCC
studies in normalized systems, and predict mucus clearability by cili-
ary and cough mechanisms on the basis of measured rheologic prop-




The xenon-133 equilibrium scan at baseline was used to create ROIs
for each subject, focused on the whole lung as well as on central and
peripheral regions, to determine regional deposition and clearance
patterns (7, 8). A rectangular region bordering the whole right lung
(to avoid activity in the stomach, was used to determine by computer
analysis the lung retention (R) of radiolabeled particles in the right
lung over the 2-h period and at 24 h, expressed as a percent of the ini-




 0. If a subject had situs inversus, the left lung was
analyzed to avoid activity in the right-sided stomach. A CP ratio of
deposition, normalized to the xenon equilibrium scan, was calculated
to assess the uniformity of deposition on the various study days. To
calculate R at a given time, the first two images of each scanning pe-
riod were averaged at that time. Retention curves were constructed
for each study day from background readings and decay rates, with
the counts corrected at 10-min intervals and normalized to the back-








 100% by definition).





mean percent radioactivity cleared was calculated by averaging the
percent cleared for each 10-min time period within the period of in-
terest (0 to 60 min and 0 to 120 min). Additionally, clearance was cal-
culated as the percent isotope cleared per minute (%/min), by divid-
ing the mean clearance by the mean time for these time periods. It
should be noted that 20 to 60 min was the period of controlled cough,
and that 0 to 120 min was the total observation period. The clearance
data were calculated for whole and peripheral lung regions, using the




Before and after aerosol dosing, patients were asked to score, on a
questionnaire sheet, the severity and type of their cough, amount,
ease of expectoration, and nature of sputum, chest tightness, and
wheezing, on a scale of 0 to 10. They were also asked to record com-




To test the hypothesis that aerosolized UTP would significantly en-
hance whole-lung clearance, we compared the mean clearance rates




 test for UTP
versus vehicle, during the specified of time periods of 0 to 60 min and
0 to 120 min. Because differences in C/P ratios between the two study
days might have produced differences in mean clearance, indepen-
dent of any UTP effect, we also compared the C/P ratio on each study




 test. As a sec-
ondary analysis, we used multivariate analysis with stepwise entry of




























, age, sex). These evaluations were done through analysis of
variance, using Systat for Macintosh (Systat Inc., Evanston, IL) and





 that as variables either spontaneous and controlled
coughs or the PFR of coughs as variables significantly affect clearance
during cough in patients with PCD, theoretical considerations and
model experiments suggest that they may be important determinants
of cough efficacy (17, 19). The questionnaires were compared for each
study day for the whole group, and were also compared qualitatively.
The total sputum weights were compared for each study day. In
addition, the time taken to produce the sputum was analyzed, and a
sputum “production rate” was calculated and compared for each
study day (i.e., if a subject produced X grams of sputum Y minutes af-
ter the commencement of the study, the sputum production rate was
calculated as X/Y grams per minute for that individual. The data were
compared for the entire group for each study day. Ion content and in-
dices of rheology for matched pairs of sputum (obtained after UTP
and vehicle) were compared on the basis of the following parameters:




















, and blood pressure) were also analyzed for subjects at
baseline and at 15 min, 30 min, and 45 min. The sputum and safety









 SEM, with significance for all statisti-








Clearance during Cough (Whole Lung)
 
















 12) are illustrated
in Figure 2. Coughing clearly increased the rate of whole-lung




 20 to 60 min. There was an
early separation between the clearance curve for vehicle and
that for UTP, which increased for the 60 min of controlled and
spontaneous coughing and was maintained for the entire study
time (120 min). It was also obvious that when there was little
or no cough (after 60 min), there was a much slower rate of














there was little clearance.
The mean rates of whole-lung clearance for UTP and vehi-
cle are summarized in Figure 3, which illustrates the clearance
of isotope for both UTP and vehicle for the periods from 0 to




 0 to 60 min:
of the radionuclide marker. Mean clearance rates were signifi-














difference was maintained for the subsequent 60 minutes of
study; the mean clearance from 0 to 120 min was also greater












 0.02). The retention of particles at
24 h was similar in both the placebo and UTP groups.
We tested whether the effect of UTP in enhancing clear-
ance during cough could reflect confounding technical vari-
Figure 2. Whole-lung clearance (6 SEM) of radiolabeled particles
over the entire study period for subjects (n 5 12) with PCD after
inhalation of UTP (triangles) and vehicle (circles).
 
 




: Aerosolized UTP in Patients with Primary Ciliary Dyskinesia 147
 
ables. Initial deposition patterns (i.e., C/P ratios) were well












 0.2). The mean number of spon-
taneous coughs from 0 to 60 min was not significantly different













 0.13). In the stepwise
entry multivariate analysis, only UTP versus vehicle predicted
the difference in clearance for both the 0 to 60 min and the 0





None of the other variables (C/P deposition ratio, number of
spontaneous coughs, or PFR of controlled coughs) were sig-
nificant dependent variables for clearance from either 0 to 60
min or 0 to 120 min. Further, the changes in clearance during
cough as a result of UTP inhalation were not predicted by any
of the characteristics of the subjects participating in the study,
such as lung function, age, or gender.
Interestingly, the mean PFR of controlled coughs was
slightly higher after inhalation of UTP than after inhalation of













study was conducted in a double blind manner, and an investi-
gator and the subject monitored each controlled cough on an
oscilloscope to attempt to match the cough efforts (and thus
peak flows) on each occasion. When entered into a separate
multivariate analysis, this difference in cough PFR was pre-









In addition to analyzing the effects of UTP on whole-lung
clearance during cough in the study subjects, we also assessed
whether any of the characteristics of the subjects were predic-
tive of baseline (i.e., after vehicle) clearance during cough. In
a multivariate analysis of mean baseline clearance during




 (% predicted) significantly


















) the mean PFRs of controlled coughs nor-









This analysis suggests that PCD patients with better lung func-
tion can more easily clear secretions by cough. This relation-












0.68), which would tend to favor increased clearance (20).
 
Clearance during Cough (Peripheral Lung)
 
In contrast to the data for the whole lung, clearance during
cough for the peripheral lung was not significantly different













 0.04%/min for vehicle versus 0.17 
 
6
0.04%/min for UTP [mean 6 SEM]).
Sputum Production Rate and Lung Symptoms
The mean weight of sputum produced after UTP tended to be
greater than after vehicle (3.40 6 0.17 g for UTP versus 2.95 6
0.50 g for vehicle, p 5 0.3). The sputum production rate in
those patients also tended to be faster after UTP, at 0.39 6
0.07 g/min versus 0.27 6 0.09 g/min after vehicle (p 5 0.08).
Among the eight patients who completed the questionnaire
after aerosol dosing, we could discern no difference in severity
of cough, chest tightness, or wheezing. Four of the eight pa-
tients noted that sputum was easier to produce after UTP, one
thought it was easier to produce after vehicle, and three could
discern no difference in ease of expectoration after either so-
lution. Because the questionnaire was not designed to be rig-
orously quantitative, the data were not subjected to statistical
analysis.
Sputum Rheology and Ion Content
The ion content (Na1 and Cl2) and indices of rheology of spu-
tum are given in Table 1 for the eight subjects for whom
matched samples were available. There was no difference be-
tween the two treatment groups in ion content, or in any of the
rheologic indices: Avg Log G, clearance during cough index,
or mucociliary index. 
Acute Safety
No acute adverse effects were noted in any of the measured
safety parameters (HR, SaO2, blood pressure) in the nine sub-
jects from whom data were obtained after administration of
aerosolized UTP. A small decrease in SaO2 (from 96.3% to
95.6%) was noted after inhalation of both UTP and vehicle
and represented a significant change from baseline. Although
these changes following both UTP and vehicle reached statis-
tical significance, they were not felt to be of any clinical signif-
icance. No arrhythmias were noted during the ECG monitor-
ing, apart from a sinus tachycardia on both study days in one
individual. This individual was noted to have the lowest FEV1
of the group (1.24 L, 43% predicted), and it was felt that the
tachycardia was a manifestation of clinical status rather than
Figure 3. Whole-lung clearance of radiolabeled particles (% of
original isotope cleared per minute 6 SEM) for the periods t 5 0
to 60 min and t 5 0 to 120 min after inhalation of UTP (U) and ve-
hicle (V). (* Different from vehicle p , 0.05.)
TABLE 1
ION CONTENT AND BIORHEOLOGIC FEATURES OF AIRWAYS
SECRETIONS FROM PATIENTS WITH PRIMARY CILIARY






(n 5 8) Normal Values†
Avg Log G, 1 rad/s 2.20 6 0.14 2.00 6 0.1 2.17 6 0.08
Cough-clearance index 1.52 6 0.17 1.74 6 0.15 1.52 6 0.03
Mucociliary-clearance index 0.89 6 0.04 0.95 6 0.02 0.91 6 0.02
Na1 content, mEq/L 125.0 6 8.3 126.0 6 8.4 N/A
Cl2 content, mEq/L* 98.0 6 11.71 100.0 6 3.80 N/A
Definition of abbreviation: N/A 5 not available.
Avg Log G is an index of mechanical impedance of sputum.
All values mean 6 SEM.
*n 5 5.
†Normal values shown for comparison (32).
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of any drug effect. One subject noted slight chest pain and
“stomach upset” after inhalation of both vehicle and UTP.
These symptoms were not felt to be related to either study so-
lution.
DISCUSSION
The pulmonary disease associated with defective MCC in
PCD, for which there is no specific treatment, results in bron-
chiectasis (5, 21). Patients with PCD have cough as a promi-
nent symptom, which serves as a compensatory mechanism for
defective MCC. This may be a partly effective backup method
for airway clearance in patients with PCD (3–5). In this pilot
study, we showed that aerosolized UTP enhances clearance
during cough in patients with PCD.
UTP represents a potential novel pharmacotherapy for air-
ways disease, directed at modulation of ion transport and
other components of the mucociliary apparatus (11, 22–24).
Acting through extracellular P2Y2 receptors, UTP stimulates
Cl2 secretion via apical calcium-activated Cl2 channels, in-
duces goblet cell degranulation, and increases CBF in normal
airway epithelia (25). Studies in normal subjects and in pa-
tients with CF (with UTP combined with amiloride) have
shown that UTP improves MCC, presumably through the in-
tegrated effects of the stimulation of CBF, and secretion of
mucins and liquid (7, 8). PCD provides a genetic model for at-
tempting to test whether clearance during cough is favorably
altered by UTP effects on mucin and ion secretion, rather than
by effects that stimulate CBF, especially since in vitro data
suggest that triphosphate nucleotides do not increase CBF (5).
In this study we elected to incorporate a series of con-
trolled coughs early in the protocol (immediately after dosing)
for two reasons. First, pilot observations of the study subjects
suggested that aerosolization of vehicle tended to induce
spontaneous cough, which would affect clearance measures.
Second, the half-life of UTP on airway surfaces is likely to be
limited after drug delivery (in vivo and in vitro studies suggest
a half-time for clearance on the order of 15 to 30 min for the
UTP concentrations relevant to this study [26, 27]). The me-
tabolism of UTP is determined by ectonucleotidases present
on airway surfaces, which rapidly degrade UTP. In the study
of aerosolized UTP in normal subjects and CF patients, phar-
macodynamic enhancement of MCC was evident for at least
50 min (7, 8). We therefore attempted to measure the effect of
UTP during cough maneuvers during that time period.
The present study supported the hypothesis that after inha-
lation of UTP as compared with vehicle, there was an increase
in the rate of clearance of radiolabeled particles during cough
from the airways of the 12 subjects with PCD. The time peri-
ods during which the difference was noted are illustrative. A
difference would have been most likely to have been evident
during the period of controlled coughing (20 to 40 min) rather
than from 60 to 120 min, when most subjects did not cough. In
those who did cough during this latter period, there was no
difference in the mean number of coughs on either study day.
It is noteworthy that the clearance during cough was not
significantly different with UTP and with vehicle for periph-
eral regions of the lungs of these PCD patients. In contrast, a
previous study in patients with CF showed that the effect of
UTP with amiloride on MCC was most notable in the periph-
eral regions of the lung (8). Since in the current study the de-
posited radionuclide was mainly in central airways (as indi-
cated by the high C/P ratios) and clearance during cough is
dominant in the central airways, the main effect of UTP in en-
hancing whole-lung but not peripheral clearance in PCD is not
surprising.
It is clear that other factors did not influence clearance dur-
ing these studies. The C/P ratios following the inhalation of
[99mTc]Fe2O3 particles reflect the pattern of radionuclide dep-
osition, and a higher C/P ratio means more marker deposited
in central (larger, proximal) airways. In this study, the C/P ra-
tios were well matched on both study days, and the C/P ratio
did not exert a significant effect when introduced into the mul-
tivariate analysis (i.e., the effect of UTP on clearance during
cough was still significant when the C/P ratio was factored into
the analysis). Although the number of spontaneous coughs
tended to be slightly higher on the UTP than on the vehicle
day, this did not have a significant effect on clearance during
cough when subjected to multivariate analysis. For the vari-
able of controlled coughs, we had the subjects monitor their
own flow patterns and mimic these patterns for each series of
coughs, while recording the peak flow of each controlled
cough. When entered into the multivariate analysis, the mean
peak flow for all subjects on each study day did not have a sig-
nificant influence on the effect of UTP in improving clearance
during cough.
An interesting observation was that the mean PFR was sig-
nificantly increased on the UTP day as compared with the ve-
hicle day (9% higher following UTP). This raises the possibil-
ity that the improved peak flow and altered airway mechanics
seen with UTP may have improved the clearance of isotope,
either by chance alone or as a direct result of the UTP inhala-
tion. When entered into a simple correlation analysis in addi-
tion to the multivariate analysis described earlier, peak flow
did not predict the difference in clearance at either 30 min or
60 min, suggesting that improved PFRs did not cause the
faster rate of clearance. The study was done in a double blind
manner, and the subjects matched their efforts in producing
controlled coughs on the two study days as much as possible,
nor were there any controlled coughs during administration of
aerosol. This argues against the improved PFRs of the con-
trolled coughs after UTP occurring by chance alone. Further-
more, UTP has not been noted to be a bronchodilator in pre-
vious studies; if anything, small decrements in FEV1 and mean
maximal expiratory flow measurements have been noted in
both normal subjects and in patients with CF (7, 8). Thus, it is
unlikely that UTP caused the improvement in airway mechan-
ics directly. A speculative explanation for the improved PFRs
following UTP is enhanced clearance of secretions early in the
cough period (i.e., during spontaneous coughing), with better
airflow mechanics. This hypothesis is supported by ANOVA
of PFR as a function of UTP versus vehicle (p 5 0.002) and of
the number of spontaneous coughs (p 5 0.04).
The actions of UTP in improving clearance during cough in
PCD are likely to reflect alterations in the volume and biorhe-
ology of airway secretions, since clearance during cough is a
function of the depth of the periciliary fluid as well as of the
rheology of the fluid layer (17, 28, 29). UTP increases the vol-
ume of airway surface liquid, which probably does improve
clearance of secretions during cough (30). Both the periciliary
and gel layers are probably likely cleared together, although
whether this specifically happens with clearance during cough
in PCD has not been tested (31). The measured ion contents
of a small number of sputum samples in this study were not
significantly different from one another, but the ion composi-
tion (tonicity) of sputum might not change if the water perme-
ability is sufficient for the osmolarity to equilibrate with that
of the isotonic submucosal liquid. The absence of any change
in rheology may reflect the small number of matched samples
available for statistical analysis, or the possibility that the
changes were modest and not detected. However, it is interest-
ing to note that the indices of rheology after administration of
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vehicle in these samples from patients with PCD were within
the previously reported normal ranges, and that clearance
during cough tended to become supranormal after administra-
tion of UTP (32). Patients with CF, on the other hand, have
abnormal indices of rheology at baseline (33).
In summary, UTP can safely be given by aerosolized deliv-
ery to patients with PCD, and is well tolerated. Whether the
acute improvement in clearance of isotope during cough after
such treatment translates into a meaningful clinical benefit re-
mains to be seen (4, 34). The enhanced clearance of particles
after UTP inhalation, with improved airway mechanics (PFRs),
coupled with a tendency toward easier and more rapid sputum
production, suggest that further clinical studies of this class of
agents are warranted.
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